References
- Jin DC. Current status of dialysis therapy for ESRD patients in KOREA. J Korean Med Assoc 2013;56(7):562- 8. https://doi.org/10.5124/jkma.2013.56.7.562
- Yang CW. Current status and future in patients with end stage renal disease in KOREA. J Korean Med Assoc 2013; 56(7):560-1. https://doi.org/10.5124/jkma.2013.56.7.560
- Li S, Foley RN, Collins AJ. Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States. Kidney Int 2004;65(5):1864-9. https://doi.org/10.1111/j.1523-1755.2004.00584.x
- Ohashi N, Sakao Y, Yasuda H, et al. Methoxy polyethylene glycol-epoetin beta for anemia with chronic kidney disease. Int J Nephrol Renovasc Dis 2012;5:53-60.
- Ahn SC, Choi SO, Shin SJ, et al. Anemia in patients with chronic renal failure on hemodialysis. Kidney Res Clin Pract 1994;13(4):769-75.
- KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006;47(5 suppl 3):S11-145. https://doi.org/10.1053/j.ajkd.2006.03.010
- Shimosaka A. Pharmacokinetics and Application of Erythropoietin Therapy: Overview of Epoetin Alfa Studies in Japan. Ann N Y Acad Sci 1994;718:111-22.
- Horl WH. Differentiating factors between erythropoiesis stimulating agents: an update to selection for anaemia of chronic kidney disease. Drugs 2013;73(2):117-30. https://doi.org/10.1007/s40265-012-0002-2
- Padhi D, Ni L, Cooke B, et al. An extended terminal halflife for darbepoetin alfa: results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis. Clin Pharmacokinet 2006;45(5):503-10. https://doi.org/10.2165/00003088-200645050-00005
- Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999;10(11):2392-5.
- Locatelli F, Reigner B. C.E.R.A.: pharmacodynamics, pharmacokinetics and efficacy in patients with chronic kidney disease. Expert Opin Investig Drugs 2007;16(10): 1649-61. https://doi.org/10.1517/13543784.16.10.1649
- Curran MP, McCormack PL. Methoxy polyethylene glycolepoetin beta: A review of its use in the management of anaemia associated with chronic kidney disease. Drugs 2008;68(8):1139-56. https://doi.org/10.2165/00003495-200868080-00009
- Dougherty FC, Reigner B, Jordan P, et al. Continuous erythropoiesis receptor activator (CERA) provides dosedependent erythropoietic activity with a prolonged half-life in healthy volunteers. Ann Oncol 2004; 15(suppl 3): iii157 (Abstr 2943).
- Macdougall IC, Robson R, Opatrna S, et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006;1:1211-5. https://doi.org/10.2215/CJN.00730306
- Klinger AS, Foley RN, Goldfarb DS, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD. Am J Kidney Dis 2013.
- Wazny LD, Stojimirovic BB, Heidenheim P, et al. Factors influencing erythropoietin compliance in peritoneal dialysis patients. Am J Kidney Dis 2002;40(3):623-8. https://doi.org/10.1053/ajkd.2002.34925
-
Lee JY, Byun SW, Yeo YS, et al. Comparison of erythropoietic effect between epoetin-
${\alpha}$ and darbepoetin-a in hemodialysis patients: A randomized crossover study. Kidney Res Clin Pract 2009;28(5):450-5. - Yoo SH, Kang JM, Kang GW, et al. Phase III clinical study of recombinant human erythropoietin (Eporon(R)) on anemia of chronic renal failure. Kidney Res Clin Pract 2000;19(6):1053- 62.
- Product Information: MIRCERA(R) injection, methoxy polyethylene glycol-eopetin beta injection. Hoffmann-La Roche,Inc, Nutley, NJ, 2007.
- Nissenson AR, Swan SK, Lindberg JS, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002;40(1):110-8. https://doi.org/10.1053/ajkd.2002.33919
- Vanrenterghem Y, Barany P, Mann JF, et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 2002;62(6):2167-75. https://doi.org/10.1046/j.1523-1755.2002.00657.x
- Shin SH, Lee YS. Determinants of erythropoietin hyporesponsiveness in management of anemia in hemodialysis patients. Kor J Clin Pharm 2011;21(2):122-30.
- Klinger M, Arias M, Vargemezis V, et al. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. Am J Kideny Dis 2007;50(6):989-1000. https://doi.org/10.1053/j.ajkd.2007.08.013
- Carrera F, Lok CE, de Francisco A, et al. Maintenance treatment of renal anemia in hemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrol Dial Transplant 2010;25(12):4009-17. https://doi.org/10.1093/ndt/gfq305
- Park SK, Hwang KS, Park JS, et al. Hemoglobin variability associated with different erythropoiesis stimulating agents in hemodialysis patients. Kidney Res Clin Pract 2011;30(1):41-7.
- Sikand H, Decter A, Greco T, et al. Cost analytic model to determine the least costly inpatient erythropoiesis stimulating therapy regimen. Ann Pharmacother 2008;42(1):16-23. https://doi.org/10.1345/aph.1K061
- Jensen JD, Madsen JK, Jensen LW. Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients. Eur J Clin Pharmacol 1996;50(3):171-7. https://doi.org/10.1007/s002280050088